• Ryan T Cleary, Hongyu Sun, Thanhthao Huynh, Simon M Manning, Yijun Li, Alexander Rotenberg, Delia M Talos, Kristopher T Kahle, Michele Jackson, Sanjay N Rakhade, Gerard T Berry, Gerard Berry, and Frances E Jensen.
• Department of Neurology, Children's Hospital Boston, Boston, Massachusetts, United States of America.
• Plos One. 2013 Jan 1;8(3):e57148.

AbstractNeonatal seizures can be refractory to conventional anticonvulsants, and this may in part be due to a developmental increase in expression of the neuronal Na(+)-K(+)-2 Cl(-) cotransporter, NKCC1, and consequent paradoxical excitatory actions of GABAA receptors in the perinatal period. The most common cause of neonatal seizures is hypoxic encephalopathy, and here we show in an established model of neonatal hypoxia-induced seizures that the NKCC1 inhibitor, bumetanide, in combination with phenobarbital is significantly more effective than phenobarbital alone. A sensitive mass spectrometry assay revealed that bumetanide concentrations in serum and brain were dose-dependent, and the expression of NKCC1 protein transiently increased in cortex and hippocampus after hypoxic seizures. Importantly, the low doses of phenobarbital and bumetanide used in the study did not increase constitutive apoptosis, alone or in combination. Perforated patch clamp recordings from ex vivo hippocampal slices removed following seizures revealed that phenobarbital and bumetanide largely reversed seizure-induced changes in EGABA. Taken together, these data provide preclinical support for clinical trials of bumetanide in human neonates at risk for hypoxic encephalopathy and seizures.

47 keywords...

hide…